Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 5/2001

01-04-2001 | Adis New Drug Profile

Bendamustine

Authors: Julia A. Barman Balfour, Karen L. Goa

Published in: Drugs | Issue 5/2001

Login to get access

Abstract

  • ▴ Bendamustine is a bifunctional alkylating agent with cytotoxic activity against human ovarian and breast cancers in vitro. It shows only partial in vitro cross-resistance with cyclophosphamide, melphalan, carmustine and cisplatin.
  • ▴ Bendamustine as monotherapy or as part of combination chemotherapy protocols for first-line or subsequent treatment produced objective response rates of 61 to 97% in patients with Hodgkin’s disease or non-Hodgkin’s lymphoma (NHL) [41 to 48% in high grade NHL].
  • ▴ In patients with multiple myeloma, a bendamustine/ prednisone regimen produced a higher rate of complete response (32 vs 11%) and more durable responses than a melphalan/prednisone regimen.
  • ▴ Substitution of bendamustine for cyclophosphamide in a standard first-line COP regimen (cyclophosphamide, vincristine and prednisolone) yielded similar response rates in patients with advanced low grade NHL.
  • ▴ Substituting bendamustine for cyclophosphamide in the CMF protocol (cyclophosphamide, methotrexate and fluorouracil) prolonged remission from 6.2 to 15.2 months in patients with metastatic breast cancer.
  • ▴ The most common adverse events in patients receiving bendamustine are haematological events and gastrointestinal disturbances. Bendamustine has a relatively low propensity to induce alopecia.
Literature
1.
Ribosepharm GmbH. Bendamustine product monograph. München, Germany, 2000
2.
Bremer K, Roth W. Bendamustine, a low toxic nitrogen-mustard derivative with high efficacy in malignant lymphomas. Tumor Diagn Ther 1996; 17(1): 1–6
3.
Strumberg D, Harstrick A, Doll K, et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996 Jun; 7: 415–21PubMedCrossRef
4.
Schwaenen C, Karakas T, Schrader M. Bendamustin in induction of apoptosis in B-cell chronic lymphocytic leukemia [abstract]. Ann Oncol 1999; 10 Suppl. 3: 132
5.
Schöffski P, Seeland G, Engel H, et al. Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours. Ann Oncol 2000 Jun; 11: 729–34PubMedCrossRef
6.
Kath R, Blumenstengel K, Fricke HJ, et al. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001; 127: 48–54PubMedCrossRef
7.
Matthias M, Preiss R, Sohr R, et al. Pharmacokinetics of bendamustine in patients with malignant tumors [abstract]. Proc Am Soc Clin Oncol 1995 Mar; 14: 458
8.
Haase D, Preiss R, Sohr R. Untersuchungen zur Plasmaeiweißbindung von Bendamustin (Cytostasan) und Ambazon. Z Klin Med 1990; 45: 1267–72
9.
Preiss R, Sohr R, Matthias M, et al. Pharmacokinetics of bendamustine (Cytostasane) in patients [in German]. Pharmazie 1985 Nov; 40: 782–4PubMed
10.
Herold M, Schulze A, Mantovani L, et al. BOP versus COP in advanced low grade non-Hodgkin’s lymphomas — results of a randomized multicenter study [abstract]. Blood 1999 Nov 15; 94 Suppl. 1 (Pt 2): 262
11.
Pönisch W, Mitrou PS, Merkle K, et al. A randomized multi-center study of bendamustine/prednisone versus melphalane/prednisone in the primary treatment of multiple myeloma [abstract no. 542]. Blood 1999; 94(10) Suppl. 1: 123a
12.
Poenisch W, Mitrou PS, Merkle KH, et al. Bendamustine/prednisone versus melphalan/prednisone in the primary treatment of multiple myeloma: an updated analysis of the 94BP01 protocol [abstract]. Blood 2000 Nov 16; 96 Suppl. 11 (Pt 1): 759a
13.
Ruffert K, Jahn H, Syrbe G, et al. Cytostasan (Bendamustin) in der Alternativetherapie maligner Non-Hodgkin-Lymphome [in German]. Z Klin Med 1989; 44: 671–4
14.
Blumenstengel K, Fricke H-J, Kath R, et al. Bendamustin (B), vincristin (O), prednisolon (P) in relapsed and refractory low-grade non-Hodgkin-lymphomas (NHL) [abstract no. 591]. Ann Hematol 1999; 77 Suppl. II: S149
15.
Gnad M, Reichle A, Andreesen R, et al. Therapy of low-grade non-Hodgkin’s-lymphoma (NHL) with fludarabine and bendamustine [abstract]. Onkologie 1999 Aug; 22 Suppl. 1: 168
16.
Ruffert K. Therapy of low grade non-Hodgkins-lymphoma (NHL) with bendamustine and oral etoposide [abstract no. 452]. Ann Oncol 1999; 10 Suppl. 5: 125
17.
König U, Junghauss C, Decker S, et al. Response of refractory and relapsed low grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia to Dexa-BID, a bendamustine hydrochloride containing regimen [abstract no. 479]. Ann Oncol 1999; 10 Suppl. 3: 132
18.
Heider A, Kress M, Niederle N. Relapse therapy with bendamustine in patients with low grade non Hodgkin lymphomas (NHL): efficacy and toxicity [abstract]. Blood 1998 Nov 15 Suppl. 1 (Pt 2): 236
19.
Heider A, Kress M, Niederle N. Bendamustin as second-line therapy in patients with relapsed low grade non-Hodgkin’s lymphoma and multiple myeloma [in German]. Tumor Diagn Ther 1997; 18: 71–5
20.
Preiss J, Heck HK, Schmidt P. Bendamustine in the therapy of low-grade malignant lymphomas [abstract]. Eur J Cancer 1999 Sep; 35 Suppl. 4: 336CrossRef
21.
Kahl C, Herold M, Höffkes HG, et al. Bendamustine, methotrexate, mitoxantrone, and prednisolone (BMMP) for the treatment of relapsed or refractory high-grade non-Hodgkin’s lymphoma. Onkologie 1997; 20(5): 406–8CrossRef
22.
Weidmann E, Kim ZC, Geduldig K, et al. Palliative treatment of high grade non Hodgkin’s lymphoma with bendamustine: a phase II study [abstract]. Onkologie 2000; 23 (Sonderheft 7): X210
23.
Herold M, Keinert K, Anger G, et al. Risk-adapted combined radiotherapy and chemotherapy for Hodgkin’s disease — results of a pilot study. Onkologie 1992; 15: 502–5CrossRef
24.
Herold M, Keinert K, Anger G. Risk adapted combined radio- and chemotherapy in Hodgkin’ s disease — 10-year follow-up. Onkologie 1999; 22(4): 310–3CrossRef
25.
Herold M, Siebert S, Schulze A, et al. Reduced combined modality treatment for Hodgkin’s disease: results of a randomized multicenter trial [abstract no. P-85]. Leuk Lymphoma 1998; 29 Suppl. 1
26.
Aivado M, Becker K, Neise M, et al. Bendamustine (B) is an efficient and well-tolerated option in the palliation of pretreated B-cell chronic lymphocytic leukemias (CLL) [poster]. 37th Annual Meeting of the American Society of Clinical Oncology (ASCO); 2001 May 12–15; San Francisco (CA)
27.
Ruffert K. Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil [in German]. Zentralbl Chir 1998; 123 Suppl. 5: 156–8PubMed
28.
Höffken K, Merkle K, Schönfelder M, et al. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol 1998; 124: 627–32PubMedCrossRef
29.
Jamitzky T, Lange OF. Third-line chemotherapy with bendamustin for metastatic breast cancer — a prospective pilot study [abstract]. Eur J Cancer A 1996; 32A Suppl. 2: 47CrossRef
30.
Schmidt P, Heck HK, Preiss J. Bendamustin/mitoxantrone in the treatment of advanced breast cancer [abstract]. Eur J Cancer 1999 Sep; 35 Suppl. 4: 324CrossRef
31.
Heider A, Köster W, Grote-Kiehn J, et al. Bendamustin in untreated small cell lung cancer (SCLC): efficacy and toxicity [abstract]. Eur J Cancer 1999 Sep; 35 Suppl. 4: 254CrossRef
32.
Reck M, Haering B, Koschel G, et al. Chemotherapy of advanced SCLC and NSCLC with bendamustine — a phase II study [in German]. Pneumologie 1998 Oct; 52: 570–3PubMed
33.
Schilcher RB, Rahn A, Haase KD. Recurrent ENT tumors treated with bendamustine or gemcitabine and radiotherapy. 36th Proc Am Soc Clin Oncol, New Orleans, 20–23 May 2000; 19: 426
34.
Ridwelski K, Rudolph St, Fahlke J, et al. Combination bendamustin (B), mitomycin (M), 5-FU (FU) and prednisolon (P) in advanced gastrointestinal tumours with progress under chemotherapy [abstract]. Eur J Cancer A 1997 Sep; 33 Suppl. 8: 283CrossRef
35.
Kollmannsberger C, Gerl A, Schleucher N, et al. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs 2000 Aug; 11: 535–9PubMedCrossRef
36.
Von Minckwitz G, Souchon R, Kleeberg UR, et al. Bendamustin, MTX, 5-FU (BMF) vs. cyclophosphamide, MTX, 5-FU (CMF) as first line therapy of metastatic breast cancer: a safety interim analysis. 36th Annual Meeting of the American Society of Oncology; 2000 May 20–23; New Orleans (LA), 120
37.
Blumenstengel K, Schmalenberg H, Fricke H-J, et al. Bendamustin monotherapy in advanced and refractory chronic lymphocytic leukemia [abstract]. Onkologie 1997 Oct; 20 Suppl. 1: 143
Metadata
Title
Bendamustine
Authors
Julia A. Barman Balfour
Karen L. Goa
Publication date
01-04-2001
Publisher
Springer International Publishing
Published in
Drugs / Issue 5/2001
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200161050-00009

Other articles of this Issue 5/2001

Drugs 5/2001 Go to the issue

Adis New Drug Profile

Bendamustine

Leading Article

Emerging Strategies in Infectious Diseases

Adis New Drug Profile

Levosimendan

Adis Drug Evaluation

Risedronate

Review Article

Current Concepts on Pathophysiology, Diagnosis and Treatment of Diffuse Oesophageal Spasm

Adis New Drug Profile

Levosimendan